Sign up
Pharma Capital

NetScientific gaining critical mass with commercial ramp-up of portfolio

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), caught up with Proactive's Andrew Scott to update on developments within the IP commercialisation specialist's portfolio.

''All of our companies are game-changing and unique in their sectors'', Martelet says.

Most recently NetScientific announced the issue by the US Patent and Trademark Office of two new patents exclusively licensed to their portfolio company, Wanda.

The patents will significantly extend protection for the core technology used in Wanda's software application for remote health and patient management.

 

View full NSCI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.